Separate terms with OR to return results that match either term.
 
Clear All

9,752 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Descending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55513-0520-06 55513-0520 Palifermin Kepivance Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF Dec. 15, 2004 Dec. 15, 2009 No Longer Used
55513-0488-02 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0488-24 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0488-96 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0478-01 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
55513-0478-10 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
55513-0326-01 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
55513-0283-01 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0283-10 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0267-01 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0267-10 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0224-01 55513-0224 rituximab-arrx Riabni 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
55513-0209-01 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-10 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-91 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0207-01 55513-0207 Bevacizumab-awwb MVASI 400.0 mg/16mL, 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous June 1, 2018 In Use
55513-0206-01 55513-0206 Bevacizumab-awwb MVASI 100.0 mg/4mL, 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous June 1, 2018 In Use
55513-0192-01 55513-0192 Pegfilgrastim Neulasta Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Feb. 20, 2015 In Use
55513-0190-01 55513-0190 Pegfilgrastim Neulasta 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous April 1, 2002 In Use
55513-0160-01 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Dec. 18, 2014 In Use
55513-0148-01 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0148-10 55513-0148 Epoetin alfa Epogen 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0144-01 55513-0144 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0144-10 55513-0144 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 16, 1993 In Use
55513-0141-01 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 28, 2019 In Use
55513-0132-01 55513-0132 trastuzumab-anns Kanjinti 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 11, 2019 In Use
55513-0126-01 55513-0126 Epoetin alfa Epogen 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 30, 1989 In Use
55513-0126-10 55513-0126 Epoetin alfa Epogen 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 30, 1989 In Use
55513-0111-01 55513-0111 Darbepoetin alfa Aranesp 300.0 ug/.6mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 14, 2006 In Use
55513-0110-01 55513-0110 Darbepoetin alfa Aranesp 300.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 14, 2006 In Use
55513-0098-01 55513-0098 Darbepoetin alfa Aranesp 10.0 ug/.4mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Oct. 6, 2015 In Use
55513-0098-04 55513-0098 Darbepoetin alfa Aranesp 10.0 ug/.4mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 26, 2006 In Use
55513-0097-01 55513-0097 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0097-91 55513-0097 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0096-01 55513-0096 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0096-91 55513-0096 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0095-01 55513-0095 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0095-91 55513-0095 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0094-01 55513-0094 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0094-91 55513-0094 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0093-01 55513-0093 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0093-91 55513-0093 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0092-01 55513-0092 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0092-91 55513-0092 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0091-01 55513-0091 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0091-91 55513-0091 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0090-01 55513-0090 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0090-91 55513-0090 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sept. 25, 2006 Feb. 28, 2009 No Longer Used
55513-0079-01 55513-0079 Talimogene Laherparepvec Imlygic 100000000.0 [PFU]/mL Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus Intralesional Nov. 2, 2015 In Use
55513-0078-01 55513-0078 Talimogene Laherparepvec Imlygic 1000000.0 [PFU]/mL Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus Intralesional Nov. 2, 2015 In Use

Found 9,752 results in 17 millisecondsExport these results